Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis Test Properties and Minimal Clinically Important Difference

被引:376
作者
du Bois, Roland M. [1 ]
Weycker, Derek [2 ]
Albera, Carlo [3 ]
Bradford, Williamson Z. [4 ]
Costabel, Ulrich [5 ,6 ]
Kartashov, Alex [2 ]
King, Talmadge E., Jr. [7 ]
Lancaster, Lisa [8 ]
Noble, Paul W. [9 ]
Sahn, Steven A. [10 ]
Thomeer, Michiel [11 ]
Valeyre, Dominique [12 ]
Wells, Athol U. [13 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, London SW3 6LR, England
[2] Policy Anal Inc, Brookline, MA USA
[3] Univ Turin, Dept Clin & Biol Sci, Turin, Italy
[4] InterMune Inc, Brisbane, CA USA
[5] Univ Duisburg, Fac Med, Essen, Germany
[6] Univ Duisburg, Ruhrlandklin, Essen, Germany
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[9] Duke Univ, Sch Med, Durham, NC USA
[10] Med Univ S Carolina, Charleston, SC 29425 USA
[11] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[12] Hosp Avicenne, AP HP, Bobigny, France
[13] Royal Brompton Hosp, London SW3 6LY, England
关键词
interstitial lung disease; idiopathic pulmonary fibrosis; forced vital capacity; minimal clinically important difference; mortality prediction; PLACEBO-CONTROLLED TRIAL; INTRAINDIVIDUAL CHANGES; HEALTH; SURVIVAL; PIRFENIDONE; VALIDATION;
D O I
10.1164/rccm.201105-0840OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Forced vital capacity (FVC) is an established measure of pulmonary function in idiopathic pulmonary fibrosis (IPF). Evidence regarding its measurement properties and minimal clinically important difference (MCID) in this population is limited. Objectives: To assess the reliability, validity, and responsiveness of FVC and estimate the MCID in patients with IPF. Methods: The study population included all 1,156 randomized patients in two clinical trials of IFN-gamma 1b. FVC and other measures of functional status were measured at screening or baseline and 24-week intervals thereafter. Reliability was assessed based on two proximal measures of FVC, validity was assessed based on correlations between FVC and other measures of functional status, and responsiveness was assessed based on the relationship between 24-week changes in FVC and other measures of functional status. Distribution-based and anchor-based methods were used to estimate the MCID. Measurements and Main Results: Correlation of percent-predicted FVC between measurements(mean interval, 18 d) was high (r = 0.93; P < 0.001). Correlations between FVC and other parameters were generally weak, with the strongest observed correlation between FVC and carbon monoxide diffusing capacity (r = 0.38; P < 0.001). Correlations between change in FVC and changes in other parameters were slightly stronger (range, r = 0.16-0.37; P < 0.001). Importantly, 1-year risk of death was more than twofold higher (P, 0.001) in patients with a 24-week decline in FVC between 5% and 10%. The estimated MCID was 2-6%. Conclusions: FVC is a reliable, valid, and responsive measure of clinical status in patients with IPF, and a decline of 2-6%, although small, represents a clinically important difference.
引用
收藏
页码:1382 / 1389
页数:8
相关论文
共 32 条
[1]  
Allison P., 1995, SURVIVAL ANAL USING
[2]  
Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646
[3]   Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].
Azuma, A ;
Nukiwa, T ;
Tsuboi, E ;
Suga, M ;
Abe, S ;
Nakata, K ;
Taguchi, Y ;
Nagai, S ;
Itoh, H ;
Ohi, M ;
Sato, A ;
Kudoh, S ;
Raghu, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047
[4]   Assessment of health-related quality of life in patients with interstitial lung disease [J].
Chang, JA ;
Curtis, JR ;
Patrick, DL ;
Raghu, G .
CHEST, 1999, 116 (05) :1175-1182
[5]  
Cohen J., 1988, Statistical power analysis for the behavioral sciences, VSecond
[6]   Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis [J].
Collard, HR ;
King, TE ;
Bartelson, BB ;
Vourlekis, JS ;
Schwarz, MI ;
Brown, KK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :538-542
[7]   High-dose acetylcysteine in idiopathic pulmonary fibrosis [J].
Demedts, M ;
Behr, J ;
Buhl, R ;
Costabel, U ;
Dekhuijzen, R ;
Jansen, HM ;
MacNee, W ;
Thomeer, M ;
Wallaert, B ;
Laurent, F ;
Nicholson, AG ;
Verbeken, EK ;
Verschakelen, J ;
Flower, CDR ;
Capron, F ;
Petruzzelli, S ;
De Vuyst, P ;
van den Bosch, JMM ;
Rodriguez-Becerra, E ;
Corvasce, G ;
Lankhorst, I ;
Sardina, M ;
Montanari, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) :2229-2242
[8]  
du Bois RM, EUR RESP SOC ANN C 2, pA3632
[9]   Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis [J].
du Bois, Roland M. ;
Weycker, Derek ;
Albera, Carlo ;
Bradford, Williamson Z. ;
Costabel, Ulrich ;
Kartashov, Alex ;
Lancaster, Lisa ;
Noble, Paul W. ;
Raghu, Ganesh ;
Sahn, Steven A. ;
Szwarcberg, Javier ;
Thomeer, Michiel ;
Valeyre, Dominique ;
King, Talmadge E., Jr. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (04) :459-466
[10]  
du Bois RM, 2011, AM J RESP CRIT CARE, V183, P1231, DOI [10.1164/rccm.201007-1179OC, 10.1164/rccm.201007.1179OC]